Home / Prices / Intravitreal injection of ranibizumab

Intravitreal injection of ranibizumab

Eye Care ≈ ¥4500-6500 (≈ $630-910) 30 min

Disclaimer: This site is a medical service platform; some page content is AI-assisted. Health-related information does not constitute medical advice. If you have any questions, please consult a healthcare professional. See full disclaimer

Description

Estimated cost for Intravitreal injection of ranibizumab at general public hospitals in China is about ¥3150-5200, and at Grade 3A hospitals about ¥4500-6500, varying by hospital tier and region.

Main Uses

Primary clinical use is intravitreal administration of ranibizumab (a recombinant humanized monoclonal antibody fragment) to inhibit vascular endothelial growth factor-A (VEGF-A) in the eye. Indications include: neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV). Treatment aims to reduce vascular leakage, inhibit abnormal blood vessel growth, stabilize or improve visual acuity, and prevent disease progression.

Normal Range

Not applicable — anti-VEGF intravitreal injection (ranibizumab) is a therapeutic procedure, not a diagnostic laboratory test with quantitative biomarker values. There is no 'normal range' for ranibizumab concentration in clinical practice; dosing is standardized (0.5 mg/0.05 mL per injection), and systemic drug levels are not routinely monitored.

Low Values - Possible Causes

N/A — this is not a measurable serum or ocular fluid assay; 'low value' does not apply. However, subtherapeutic effect may result from: 1) Inadequate dosing frequency (e.g., extended dosing intervals beyond disease activity), 2) Poor drug penetration due to vitreous opacities or fibrosis, 3) Development of neutralizing anti-ranibizumab antibodies (rare), 4) Non-adherence to treatment protocol, 5) Underlying disease resistance (e.g., persistent VEGF-independent angiogenesis).

High Values - Possible Causes

N/A — no clinically defined 'high value' exists. Potential concerns related to excessive exposure include: 1) Off-label repeated injections without evidence-based justification, 2) Accidental overdose (e.g., dosing error — extremely rare with prefilled syringes), 3) Systemic absorption leading to elevated free VEGF inhibition (theoretical risk of hypertension or thromboembolism), 4) Concomitant use of other anti-angiogenic agents, 5) Pre-existing systemic conditions exacerbating anti-VEGF effects (e.g., uncontrolled hypertension, recent stroke).

ranibizumab injection intravitreal injection anti-VEGF therapy

≈ ¥4500-6500

≈ $630-910

Duration: 30 min